Three-eyed ancient predator ‘unlike any living animal' discovered
The fossil species, named Mosura fentoni for resembling the fictional Japanese kaiju Mothra, was about the size of an index finger with three eyes, spiny jointed claws, a circular mouth lined with teeth, and a body with swimming flaps along its sides, researchers from the Royal Ontario Museum said.
Mosura fentoni, also dubbed 'sea moth' due to its broad swimming flaps and narrow abdomen, was a member of an extinct group of animals called radiodonts, which included the meter-long marine predator Anomalocaris canadensis.
It was, researchers said, 'unlike any living animal'.
Mosura had a unique abdomen-like body region with multiple segments at its back end, according to a new study published in the journal Royal Society Open Science.
'This is a neat example of evolutionary convergence with modern groups like horseshoe crabs, woodlice, and insects, which share a batch of segments bearing respiratory organs at the rear of the body," study co-author Joe Moysiuk said.
Scientists said it was not clear why Mosura had this unique body adaptation but suspected it could be related to a particular habitat preference requiring more efficient respiration.
It was distantly related to modern moths and belonged to a deeper branch of arthropods including spiders, crabs and millipedes.
"Radiodonts were the first group of arthropods to branch out in the evolutionary tree, so they provide key insight into ancestral traits for the entire group,' Jean-Bernard Caron, another author of the study, said.
'The new species emphasises these early arthropods were already surprisingly diverse and were adapting in a comparable way to their distant modern relatives.'
Mosura did not have arteries and veins, but an "open" circulatory system that involved the heart pumping blood into large internal body cavities called lacunae. "The well-preserved lacunae of the circulatory system in Mosura help us to interpret similar, but less clear features that we've seen before in other fossils,' Dr Moysiuk said.
The Burgess Shale fossil grounds in Canada's Yoho and Kootenay National Parks are recognised as Unesco World Heritage Sites. 'Very few fossil sites in the world offer this level of insight into soft internal anatomy. We can see traces representing bundles of nerves in the eyes that would have been involved in image processing, just like in living arthropods,' Dr Caron said, adding that the 'details are astounding'.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
25 minutes ago
- Business Wire
ClearStrand-ASD, First-of-Its-Kind Autism Screening Tool, Now Available in Japan
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- LinusBio, a leader in precision exposome medicine, announced today that ClearStrand-ASD™, its biochemical autism screening test, is now available to patients and providers in Japan for research use through its partnership with YAC Bio. This milestone marks LinusBio's first international expansion and represents a significant step in the company's mission to enable earlier identification of autism spectrum disorder (ASD) globally. Today marks a transformational moment in our mission to make early autism screening accessible worldwide. Share ClearStrand-ASD requires only a strand of hair to detect molecular signatures associated with autism spectrum disorder. This innovative, non-invasive approach provides healthcare providers with an objective screening method that can help identify ASD risk as early as one month of age, allowing families to pursue intervention during the most crucial period of early development. "Today marks a transformational moment in our mission to make early autism screening accessible worldwide," said Dr. Manish Arora, Founder and CEO of LinusBio. "Japan represents our first step beyond U.S. borders, and we chose this market because of its sophisticated healthcare infrastructure and commitment to pediatric developmental care. Japanese families dealing with autism concerns will now have access to the same cutting-edge screening technology that has already helped multiple American families get answers earlier than ever before." The Japanese launch builds on ClearStrand-ASD's successful rollout across the United States, where it is now available in 49 states. YAC Bio will partner with hospital systems in Japan to facilitate the implementation of this first-of-its-kind biomarker test for autism. LinusBio's expansion into Japan is facilitated through its existing partnership with YAC Bio (part of Y.A.C. Holdings), the Japanese multinational that invested over 1 billion yen in the company. Beyond providing market access, Y.A.C. Holdings contributes manufacturing expertise and automation capabilities that support LinusBio's scaling efforts globally. "By combining the world's only hair-cutting robotics technology with the innovative hair exposome analysis developed by LinusBio in the United States, we have contributed to the development of the world's first biomarker screening test for autism spectrum disorder. Following its launch in the U.S., we are now offering this test in Japan through our group company, YAC Bio," said Takefumi Momose, President and CEO, Y.A.C. Holdings Co., Ltd. "We sincerely hope that this test will support individuals, families, and communities in Japan who are concerned about autism." The Japan availability of ClearStrand-ASD represents the first phase of LinusBio's international expansion strategy, with the company evaluating additional markets where ClearStrand-ASD could address unmet needs in early autism detection. About ClearStrand-ASD ClearStrand-ASD is a biochemical test intended to help health care providers rule out autism spectrum disorder (ASD) in children 1 to 48 months. The test analyzes a strand of hair to map the dynamic patterns of an individual's unique biological responses at a molecular level to environmental exposures over time and uses an algorithm to assess the likelihood of autism. It is not a genetic test and must be ordered by a licensed health care provider (Rx only). ClearStrand-ASD is performed at LinusBio's CLIA-certified laboratory (CLIA #31d2307499). For more information visit: About LinusBio LinusBio (Linus Biotechnology Inc.) is a patient-centric, breakthrough science precision exposome medicine company headquartered in New Jersey. The Company's program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology. LinusBio is actively exploring additional international partnerships to expand global access to its innovative diagnostic solutions. For more information, visit About Y.A.C. Holdings Y.A.C. Holdings is a Japan-based company specializing in developing, designing, and manufacturing mechatronics-related products. The company collaborates with LinusBio on hardware innovations to scale testing capacity, driving breakthroughs in robotics and laboratory automation.
Yahoo
2 days ago
- Yahoo
Firefly Aerospace eyes Japan rocket launches for Asia market
By Kantaro Komiya TOKYO (Reuters) -Firefly Aerospace is exploring an option to launch its Alpha rocket from Japan as the U.S. rocket maker expands its satellite launch services globally, a Japanese company operating a spaceport in the country's northern Hokkaido said on Monday. The plan could make Japan the second offshore launch site - and first in Asia - for Firefly, the Texas-based rival to Elon Musk's market leader SpaceX, which had its Nasdaq debut earlier this month and is preparing for an Alpha launch in Sweden. Space Cotan, operator of the Hokkaido Spaceport located about 820 km (510 mi) northeast of Tokyo, said it and Firefly signed a preliminary agreement to study the feasibility of launching the small-lift rocket Alpha from there. Launching Alpha from Japan "would allow us to serve the larger satellite industry in Asia and add resiliency for U.S. allies with a proven orbital launch vehicle," Adam Oakes, Firefly's vice president of launch, said in a statement published on Space Cotan's website. A feasibility study would be conducted to assess the regulatory hurdles, timeframe and investments for a launch pad for Alpha in Hokkaido, said Space Cotan spokesperson Ryota Ito. The plan would require a space technology safeguards agreement (TSA) between Washington and Tokyo that would allow American rocket launches in Japan, Ito added. The governments last year kicked off the negotiations but have not reached an agreement. A U.S.-Sweden TSA signed in June cleared the path for Firefly's launches from the Arctic. Four of Firefly's six Alpha flights since 2021 have ended in failure, most recently in April. While Japan's national space agency has launched rockets for decades, private rockets are nascent and most Japanese satellite operators rely on foreign options such as SpaceX's Falcon 9 or Rocket Lab's Electron. Previously, U.S. company Virgin Orbit aimed to use Japan's southwest Oita Airport for launches but the plan was scrapped after the firm went bankrupt in 2023. Colorado-based Sierra Space has an ongoing plan to land its spaceplane on Oita beyond 2027. Taiwanese firm TiSpace last month conducted what could be the first foreign launch in Hokkaido, but the suborbital flight failed within a minute. Japan's government is targeting 30 launches of Japanese rockets a year by the early 2030s and subsidises domestic enterprises such as Space One and Toyota-backed Interstellar Technologies.
Yahoo
2 days ago
- Yahoo
High Growth Tech Stocks in Asia Featuring Takara Bio and Two Others
As Asian markets continue to navigate a complex landscape of economic indicators and trade negotiations, the tech sector stands out with its potential for high growth, driven by innovation and evolving consumer demands. In this environment, identifying promising stocks involves looking for companies that demonstrate resilience and adaptability in the face of changing market conditions, such as those featured in our discussion on Takara Bio and two other noteworthy tech firms. Top 10 High Growth Tech Companies In Asia Name Revenue Growth Earnings Growth Growth Rating Accton Technology 22.79% 22.79% ★★★★★★ Ugreen Group 20.48% 26.05% ★★★★★★ Shanghai Huace Navigation Technology 25.38% 24.34% ★★★★★★ PharmaEssentia 31.53% 65.34% ★★★★★★ Fositek 31.22% 40.16% ★★★★★★ Eoptolink Technology 33.64% 33.77% ★★★★★★ Shengyi Electronics 26.23% 37.08% ★★★★★★ Gold Circuit Electronics 26.64% 35.16% ★★★★★★ eWeLLLtd 24.93% 24.09% ★★★★★★ CARsgen Therapeutics Holdings 100.40% 118.16% ★★★★★★ Click here to see the full list of 180 stocks from our Asian High Growth Tech and AI Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Takara Bio Simply Wall St Growth Rating: ★★★★☆☆ Overview: Takara Bio Inc. operates in the fields of reagents, equipment, contract services, and genetic medicine across various regions including Japan, China, Asia, the United States, and Europe with a market capitalization of ¥107.53 billion. Operations: Takara Bio generates revenue through its diverse operations in reagents, equipment, contract services, and genetic medicine across multiple regions. The company focuses on leveraging its expertise in biotechnology to provide innovative solutions for research and healthcare applications. Takara Bio, a contender in Asia's high-growth tech sector, showcases a robust earnings trajectory with an annual growth rate of 29.66%, significantly outpacing the broader Japanese market's 8%. Despite a substantial one-off loss of ¥531M impacting its recent financials, the company has demonstrated exceptional profit growth over the past year at 406.1%, dwarfing the biotech industry's average of 11.6%. However, challenges persist as its revenue growth projection stands at just 4.9% per year, slightly above Japan's market average but below high-growth benchmarks. The firm's R&D commitment is crucial for sustaining innovation and competitiveness in this rapidly evolving sector. Dive into the specifics of Takara Bio here with our thorough health report. Learn about Takara Bio's historical performance. Good Will Instrument Simply Wall St Growth Rating: ★★★★★☆ Overview: Good Will Instrument Co., Ltd. specializes in the production and distribution of electrical test and measurement instruments for educational and industrial manufacturing sectors, with a market cap of NT$7.57 billion. Operations: Good Will Instrument generates revenue primarily from the sale of electronic test and measurement instruments, totaling NT$2.85 billion. The company serves both educational and industrial manufacturing markets. Good Will Instrument, amid Asia's competitive tech landscape, is demonstrating robust growth with reported annual revenue and earnings increases of 50.8% and 49.5%, respectively. This performance significantly surpasses the TW market averages of 10.1% for revenue and 15.3% for earnings growth, highlighting its potential in a rapidly evolving sector. The company's commitment to innovation is evident from its R&D investments, crucial for maintaining its competitive edge in technology development. Recent financials reveal a strong upward trajectory with first-half sales reaching TWD 1.37 billion, up from TWD 1.32 billion year-over-year, complemented by a net income rise to TWD 174.4 million from TWD 146.28 million in the previous period. Click here to discover the nuances of Good Will Instrument with our detailed analytical health report. Review our historical performance report to gain insights into Good Will Instrument's's past performance. Sercomm Simply Wall St Growth Rating: ★★★★☆☆ Overview: Sercomm Corporation is engaged in the research, development, manufacturing, and sale of networking communication software and equipment across North America, Europe, and the Asia Pacific with a market capitalization of NT$31.02 billion. Operations: The company's primary revenue stream comes from its computer networks segment, generating NT$50.45 billion. Sercomm's recent financial performance indicates a challenging phase, with second-quarter sales dropping to TWD 12.2 billion from TWD 13.7 billion year-over-year and net income falling significantly to TWD 334.32 million from TWD 545.21 million. Despite these setbacks, the company is actively enhancing its strategic partnerships, notably with Vecima Networks, to strengthen its position in the PON technology sector for broadband services—a move that could stabilize and potentially increase future revenue streams. Additionally, Sercomm has demonstrated a commitment to shareholder returns by repurchasing over 3 million shares for TWD 302.29 million earlier this year, reflecting confidence in its operational adjustments and market strategy moving forward. Get an in-depth perspective on Sercomm's performance by reading our health report here. Assess Sercomm's past performance with our detailed historical performance reports. Key Takeaways Click here to access our complete index of 180 Asian High Growth Tech and AI Stocks. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Want To Explore Some Alternatives? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include TSE:4974 TWSE:2423 and TWSE:5388. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data